Therefore, we hypothesize that renalase plays a critical role in the pathogenesis of MASLD/MASH by regulating triglyceride metabolism through Akt–SREBP‐1c signaling pathways. Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.